Replies to post #3038 on Statera BioPharma Inc (STAB)

[NoamCohen]

$STAB is poised to reach several clinical milestones in 2022, which will benefit patients with conditions ranging from Crohn's disease to SARS-CoV-2 viral infections

[ButterCookie]

I agree. This NASDAQ company is visionary and revolutionary that should catches the eyes of smart-informed investors
$STAB